20 reports of this reaction
3.0% of all HYPERICUM PERFORATUM reports
#3 most reported adverse reaction
SUICIDAL IDEATION is the #3 most commonly reported adverse reaction for HYPERICUM PERFORATUM, manufactured by Energique, Inc. There are 20 FDA adverse event reports linking HYPERICUM PERFORATUM to SUICIDAL IDEATION. This represents approximately 3.0% of all 666 adverse event reports for this drug.
Patients taking HYPERICUM PERFORATUM who experience suicidal ideation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDAL IDEATION is a less commonly reported adverse event for HYPERICUM PERFORATUM, but still significant enough to appear in the safety profile.
In addition to suicidal ideation, the following adverse reactions have been reported for HYPERICUM PERFORATUM:
The following drugs have also been linked to suicidal ideation in FDA adverse event reports:
SUICIDAL IDEATION has been reported as an adverse event in 20 FDA reports for HYPERICUM PERFORATUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDAL IDEATION accounts for approximately 3.0% of all adverse event reports for HYPERICUM PERFORATUM, making it one of the most commonly reported side effect.
If you experience suicidal ideation while taking HYPERICUM PERFORATUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.